We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App





Researchers Testing Do-It-Yourself COVID-19 Vaccine on Themselves

By HospiMedica International staff writers
Posted on 04 Aug 2020
A group of researchers have formed the Rapid Deployment Vaccine Collaborative (RaDVaC), developed their own do-it-yourself COVID-19 vaccine and begun testing the vaccine on themselves.

RaDVaC members come from a range of backgrounds and professions, but most of them are trained scientists and engineers. More...
This expanding core group met through their associations with Harvard Medical School and HMS Professor George Church. The project was launched in the Boston area but is expanding steadily across the US and throughout the world.

RaDVaC’s mission is rapid development, testing, and public sharing of vaccine recipes that are simple enough to be produced and administered by individual citizen scientists and qualified healthcare professionals. The group of researchers has drawn on decades of scientific literature describing proven vaccine designs to develop, produce, and self-administer an intranasally delivered vaccine. RaDVaC members have designed, produced, and self-administered several progressive generations of nasal vaccines against SARS-CoV-2. Currently, over 20 of them have self-administered the vaccine which is made up of fragments (peptides) of the virus, similar to the ones already being used for hepatitis B and human papillomavirus.

The group has not filed any patents or other intellectual property protections, and all information on their vaccine designs, material procurement, production, self-administration, and testing are freely shared on their website. In addition to publicly releasing the results of our vaccine work, RaDVaC is working with other researchers to advance new kinds of testing to assess immunity. The group aims to motivate others around the world to build on their efforts, to share their research openly, and to deploy protective vaccines rapidly and safely.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.